Amarin Corp Plc (AMRN)

[Ajax133]

HD: In many cases of an interim look with sufficient
efficacy, the only reason they may not stop the trial
would be to have more patients from a safety point of
view. I honestly can't think of any safety issues, but
with the historical animosity between FDA and AMRN,
it's not an easy call. FDA never forgets a grudge. Let's
hope AMRN has wisely done some fence mending.